Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome. A pharmaceutical composition for the treatment or prevention of hyperuricemia, which comprises an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as an insulin sensitivity enhancer, in which: R1a, R2a...

Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment or prevention of pancreatitis.

Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl) ethylideneaminooxy]-ethoxy}benzyl) thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2yl-methoxy)benzyl} thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmetho...

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)b...

Medicinal compositions for inhibiting apoptosis which contain as the active ingredient troglitazone or pharmacologically acceptable salts thereof.

Problem: to provide a glutathione reductase activity potentiator. Means for resolution: a glutathione reductase potentiator containing troglitazone or a pharmacologically acceptable salt thereof.

The 2R-diastereoisomeric pair of troglitazone show greater potency and selectivity as an agonist of peroxisome proliferator activated receptor (PPAR-gamma) than the 2S-diastereoisomeric pair. Best results are achieved with the (2R, 5S)-stereoisomer alone. The invention therefore provides improved hypoglycaemics for the treatment of type II non-insulin dependent diabetes mellitus (NIDDM).